Investor Relations
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
CiVax™ Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine - September 10, 2020 Transcript & Audio
Shareholder Update Letter - July 20, 2020
Positive Phase 3 CTCL Results - March 19, 2020 Call Transcript
 |
Interview with Soligenix Chief Medical Officer, Dr. Richard Straube, Regarding the Upcoming Phase 3 CTCL Data Readout
Dr. Brian Poligone, Clinical Investigator for CTCL Phase 3 FLASH Study, Answers Questions About Patient Care and Treatment Options
|
29 Emmons Drive
Suite B-10 Princeton, NJ 08540
Telephone: 609-538-8200
ir@soligenix.com
If you would like to receive our Investor Relations updates, please sign up for email alerts.